BioReliance bought out of parent company
BioReliance Manufacturing, a German biotech company, has been purchased from its parent company Invitrogen Europe by a consortium headed by Dr Thomas Pultar, BioReliance's managing director.
BioReliance Manufacturing, a German biotech company, has been purchased from its parent company Invitrogen Europe by a consortium headed by Dr Thomas Pultar, BioReliance's managing director.
The company will now operate under the name BIOMEVA, and will continue along the same contract manufacturing vein as BioReliance, offering fermentation and purification services using recombinant and natural microorganisms to produce APIs in lots of up to 1,000 L.
According to Pultar, who will continue as md with the existing management team, the buyout does however offer the opportunity "to exercise the high degree of flexibility of a small company and to utilise our strengths to become even more customer-oriented in future".
"This is a win-win situation for Invitrogen and BIOMEVA," said Bernd Brust, vice president and general manager of Invitrogen Europe. "Bacterial contract manufacturing was not aligned with our strategic direction, and with the new ownership of the operation by BIOMEVA, clients will continue to be well served in the years ahead. BIOMEVA will retain the current management and gain the flexibility to aggressively pursue opportunities as an independent business."
Terms of the acquisition were not disclosed.